Invivyd, Inc. (IVVD) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the second quarter in Vivid Earnings Conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. Instructions will be given at that time. As a reminder, this call may be recorded. I'd now like to turn the call over to Katie Falzone, Vice President, Corporate Controller. Please go ahead. Thank you, operator. A short while ago, we issued a press release announcing our Q2 2024 financial results and recent business highlights. That press release and the slides that are being used in today's webcast can be found in the investor section of the InVivid website under the press releases and events and presentation sections, respectively. Today's discussion will be led by Mark Aulia, chairperson of InVivid's board of directors and chairperson of the executive committee of the board. He is joined by Tim Lee, chief commercial officer, Bill Duke, Chief Financial Officer, Dr. Robert Allen, Chief Scientific Officer, and Dr. Mark Winterson, Senior Vice President of Clinical Development and Medical Affairs. During today's discussion, we will be making forward-looking statements concerning, among other things, our corporate and commercial strategy, our research and development activities, our pipeline and regulatory plans, certain financial guidance, our future prospects, and other statements that are not historical facts. These forward-looking statements are covered within the meaning of the Private Securities Litigation and Reform Act and are subject to various risks, assumptions, and uncertainties that may change over time and cause our actual results to differ materially from those expressed or implied today. These forward-looking statements speak only as of the date...